CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
escitalopram +2 moredrug
Likely dose
escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00404755
NCT00404755Phase 4Completed
CompareCT.gov

Dichotic Listening as a Predictor of Medication Response in Depression

New York State Psychiatric Institute·interventional·Posted Nov 29, 2006·Updated Apr 30, 2018

In Brief

A Phase 4 clinical trial evaluating escitalopram, bupropion, and 1 other intervention for Major Depressive Disorder and Dysthymia. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different type of commonly used anti-depressant, bupropion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Dysthymia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 29, 2006
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.6 years ago

Interventions

escitalopramdrug

Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d

bupropiondrug

bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d

imipraminedrug

imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted